Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
2017-01-01 Guazzelli, A.; Bakker, E.; Tian, K.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L.
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma
2007-01-01 Landi, S.; Gemignani, F.; Neri, M.; Barale, R.; Bonassi, S.; Bottari, F.; Canessa, P. A.; Canzian, F.; Ceppi, M.; Filiberti, R.; Ivaldi, G. P.; Mencoboni, M.; Scaruffi, P.; Tonini, G. P.; Mutti, L.; Puntoni, R.
Immunotherapy advances for mesothelioma treatment
2017-01-01 Bakker, E.; Guazzelli, A.; Ashtiani, F.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L.
Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells
2016-01-01 Fiorillo, M.; Lamb, R.; Tanowitz, H. B.; Mutti, L.; Krstic-Demonacos, M.; Cappello, A. R.; Martinez-Outschoorn, U. E.; Sotgia, F.; Lisanti, M. P.
Identification of overexpressed genes in malignant pleural mesothelioma
2021-01-01 Morani, F.; Bisceglia, L.; Rosini, G.; Mutti, L.; Melaiu, O.; Landi, S.; Gemignani, F.
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
2014-01-01 Melaiu, O.; Stebbing, J.; Lombardo, Y.; Bracci, E.; Uehara, N.; Bonotti, A.; Cristaudo, A.; Foddis, R.; Mutti, L.; Barale, R.; Gemignani, F.; Giamas, G.; Landi, S.
Expression status of candidate genes in mesothelioma tissues and cell lines
2015-01-01 Melaiu, O.; Melissari, E.; Mutti, L.; Bracci, E.; De Santi, C.; Iofrida, C.; Di Russo, M.; Cristaudo, A.; Bonotti, A.; Cipollini, M.; Garritano, S. I.; Foddis, R.; Lucchi, M.; Pellegrini, S.; Gemignani, F.; Landi, S.
Anti-CTLA-4 therapy for malignant mesothelioma
2017-01-01 Guazzelli, A.; Bakker, E.; Krstic-Demonacos, M.; Lisanti, M. P.; Sotgia, F.; Mutti, L.
Therapies currently in Phase II trials for malignant pleural mesothelioma
2013-01-01 Pinton, G.; Manente, A. G.; Tavian, D.; Moro, L.; Mutti, L.
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
2017-01-01 Bakker, E.; Guazzelli, A.; Krstic-Demonacos, M.; Lisanti, M.; Sotgia, F.; Mutti, L.
Surgery for malignant pleural mesothelioma: An international guidelines review
2018-01-01 Ricciardi, S.; Cardillo, G.; Zirafa, C. C.; Carleo, F.; Facciolo, F.; Fontanini, G.; Mutti, L.; Melfi, F.
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
2001-01-01 Strizzi, L.; Catalano, A.; Vianale, G.; Orecchia, S.; Casalini, A.; Tassi, G.; Puntoni, R.; Mutti, L.; Procopio, A.
Malignant mesothelioma as both a challenge and an opportunity
2004-01-01 Mutti, L.; Broaddus, V. C.
Estrogen receptor-β affects the prognosis of human malignant mesothelioma
2009-01-01 Pinton, G.; Brunelli, E.; Murer, B.; Puntoni, R.; Puntoni, M.; Fennell, D. A.; Gaudino, G.; Mutti, L.; Moro, L.
Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells
2013-01-01 Valenti, D.; De Bari, L.; Manente, G. A.; Rossi, L.; Mutti, L.; Moro, L.; Vacca, R. A.
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro
2000-01-01 Porta, C.; Danova, M.; Orengo, A. M.; Ferrini, S.; Moroni, M.; Gaggero, A.; Libener, R.; Betta, P. G.; Ferrari, S.; Procopio, A.; Strizzi, L.; Mutti, L.
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases
2008-01-01 Neri, M.; Ugolini, D.; Dianzani, I.; Gemignani, F.; Landi, S.; Cesario, A.; Magnani, C.; Mutti, L.; Puntoni, R.; Bonassi, S.
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?
2002-01-01 Porta, C.; Rizzo, V.; Zimatore, M.; Sartore-Bianchi, A.; Danova, M.; Mutti, L.
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
2007-01-01 Cristaudo, A.; Foddis, R.; Vivaldi, A.; Guglielmi, G.; Dipalma, N.; Filiberti, R.; Neri, M.; Ceppi, M.; Paganuzzi, M.; Ivaldi, G. P.; Mencoboni, M.; Canessa, P. A.; Ambrosino, N.; Chella, A.; Mutti, L.; Puntoni, R.
Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes
1998-01-01 Mutti, L.; Valle, M. T.; Balbi, B.; Orengo, A. M.; Lazzaro, A.; Alciato, P.; Gatti, E.; Betta, P. G.; Pozzi, E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma | 1-gen-2017 | Guazzelli, A.; Bakker, E.; Tian, K.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L. | |
| Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma | 1-gen-2007 | Landi, S.; Gemignani, F.; Neri, M.; Barale, R.; Bonassi, S.; Bottari, F.; Canessa, P. A.; Canzian, F.; Ceppi, M.; Filiberti, R.; Ivaldi, G. P.; Mencoboni, M.; Scaruffi, P.; Tonini, G. P.; Mutti, L.; Puntoni, R. | |
| Immunotherapy advances for mesothelioma treatment | 1-gen-2017 | Bakker, E.; Guazzelli, A.; Ashtiani, F.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L. | |
| Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells | 1-gen-2016 | Fiorillo, M.; Lamb, R.; Tanowitz, H. B.; Mutti, L.; Krstic-Demonacos, M.; Cappello, A. R.; Martinez-Outschoorn, U. E.; Sotgia, F.; Lisanti, M. P. | |
| Identification of overexpressed genes in malignant pleural mesothelioma | 1-gen-2021 | Morani, F.; Bisceglia, L.; Rosini, G.; Mutti, L.; Melaiu, O.; Landi, S.; Gemignani, F. | |
| MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma | 1-gen-2014 | Melaiu, O.; Stebbing, J.; Lombardo, Y.; Bracci, E.; Uehara, N.; Bonotti, A.; Cristaudo, A.; Foddis, R.; Mutti, L.; Barale, R.; Gemignani, F.; Giamas, G.; Landi, S. | |
| Expression status of candidate genes in mesothelioma tissues and cell lines | 1-gen-2015 | Melaiu, O.; Melissari, E.; Mutti, L.; Bracci, E.; De Santi, C.; Iofrida, C.; Di Russo, M.; Cristaudo, A.; Bonotti, A.; Cipollini, M.; Garritano, S. I.; Foddis, R.; Lucchi, M.; Pellegrini, S.; Gemignani, F.; Landi, S. | |
| Anti-CTLA-4 therapy for malignant mesothelioma | 1-gen-2017 | Guazzelli, A.; Bakker, E.; Krstic-Demonacos, M.; Lisanti, M. P.; Sotgia, F.; Mutti, L. | |
| Therapies currently in Phase II trials for malignant pleural mesothelioma | 1-gen-2013 | Pinton, G.; Manente, A. G.; Tavian, D.; Moro, L.; Mutti, L. | |
| Current and prospective pharmacotherapies for the treatment of pleural mesothelioma | 1-gen-2017 | Bakker, E.; Guazzelli, A.; Krstic-Demonacos, M.; Lisanti, M.; Sotgia, F.; Mutti, L. | |
| Surgery for malignant pleural mesothelioma: An international guidelines review | 1-gen-2018 | Ricciardi, S.; Cardillo, G.; Zirafa, C. C.; Carleo, F.; Facciolo, F.; Fontanini, G.; Mutti, L.; Melfi, F. | |
| Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma | 1-gen-2001 | Strizzi, L.; Catalano, A.; Vianale, G.; Orecchia, S.; Casalini, A.; Tassi, G.; Puntoni, R.; Mutti, L.; Procopio, A. | |
| Malignant mesothelioma as both a challenge and an opportunity | 1-gen-2004 | Mutti, L.; Broaddus, V. C. | |
| Estrogen receptor-β affects the prognosis of human malignant mesothelioma | 1-gen-2009 | Pinton, G.; Brunelli, E.; Murer, B.; Puntoni, R.; Puntoni, M.; Fennell, D. A.; Gaudino, G.; Mutti, L.; Moro, L. | |
| Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells | 1-gen-2013 | Valenti, D.; De Bari, L.; Manente, G. A.; Rossi, L.; Mutti, L.; Moro, L.; Vacca, R. A. | |
| Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro | 1-gen-2000 | Porta, C.; Danova, M.; Orengo, A. M.; Ferrini, S.; Moroni, M.; Gaggero, A.; Libener, R.; Betta, P. G.; Ferrari, S.; Procopio, A.; Strizzi, L.; Mutti, L. | |
| Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases | 1-gen-2008 | Neri, M.; Ugolini, D.; Dianzani, I.; Gemignani, F.; Landi, S.; Cesario, A.; Magnani, C.; Mutti, L.; Puntoni, R.; Bonassi, S. | |
| Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity? | 1-gen-2002 | Porta, C.; Rizzo, V.; Zimatore, M.; Sartore-Bianchi, A.; Danova, M.; Mutti, L. | |
| Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer | 1-gen-2007 | Cristaudo, A.; Foddis, R.; Vivaldi, A.; Guglielmi, G.; Dipalma, N.; Filiberti, R.; Neri, M.; Ceppi, M.; Paganuzzi, M.; Ivaldi, G. P.; Mencoboni, M.; Canessa, P. A.; Ambrosino, N.; Chella, A.; Mutti, L.; Puntoni, R. | |
| Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes | 1-gen-1998 | Mutti, L.; Valle, M. T.; Balbi, B.; Orengo, A. M.; Lazzaro, A.; Alciato, P.; Gatti, E.; Betta, P. G.; Pozzi, E. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista38797
- 2 Contributo in Volume2
Data di pubblicazione
- In corso di stampa29
- 2020 - 202610567
- 2010 - 201912538
- 2000 - 20098046
- 1990 - 19995281
- 1980 - 19892072
- 1970 - 1979262
- 1966 - 19694
Editore
- EDP Sciences2
- Eliseo Ranzi, Katharina Kohse-Höi...2
- Humana Press Inc.2
- Wiley Online Library2
- Brill1
- Cambridge University Press: 20111
- Edizioni dell'U.M.I.1
- Elsevier1
- GIOVANNI COSTA1
- IFIP1
Rivista
- PHYSICAL REVIEW LETTERS179
- PLOS ONE150
- IEEE TRANSACTIONS ON ELECTROMAGNE...141
- L'INDUSTRIA DELLE COSTRUZIONI140
- APPLIED SCIENCES137
- PHYSICAL REVIEW. B, CONDENSED MAT...135
- INTERNATIONAL JOURNAL OF MOLECULA...131
- SCIENTIFIC REPORTS125
- TRANSPLANTATION PROCEEDINGS118
- ENERGIES106
Serie
- METHODS IN MOLECULAR BIOLOGY2
Keyword
- Humans1211
- Female618
- Male577
- Adult341
- Italy311
- Middle Aged300
- Aged247
- COVID-19240
- Neurology (clinical)227
- Child212
Lingua
- eng27811
- ita5263
- fre99
- spa97
- ger42
- lat9
- pol7
- por6
- rus6
- enm5
Accesso al fulltext
- no fulltext27069
- open8257
- restricted2454
- reserved922
- partially open90
- mixed4
- embargoed3